Veeva and Sarah Cannon Research Institute Join Forces to Accelerate Oncology Clinical Trials

Strategic Collaboration Between Veeva Systems and Sarah Cannon Research Institute

In a significant advancement for clinical research in oncology, Veeva Systems (NYSE: VEEV) has partnered with the Sarah Cannon Research Institute (SCRI) to enhance the execution of clinical trials. Announced on June 4, 2025, this collaboration aims to improve the efficiency and speed of oncology trials conducted at more than 200 SCRI research sites. By integrating the Veeva Clinical Platform, SCRI will unify its contract research organization (CRO) and site management organization (SMO) under a single platform, ensuring streamlined data flow between clinical teams and research sites.

Yazhene Krishnaraj, SCRI's Chief Information and Digital Officer, expressed excitement about the collaboration, stating, “We are thrilled to enhance our clinical trials by integrating the Veeva Clinical Platform into our digital toolkit. This strategic partnership enables our clinical teams to provide innovative treatments to patients with greater precision and speed.” The collaboration aims to simplify and standardize trial processes, thereby improving the way researchers and clinical teams collaborate and share data.

The Veeva Clinical Platform brings a comprehensive and connected solution for clinical operations and data applications. This end-to-end platform includes Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Clinical Workbench (CDB), Randomization and Trial Supply Management (RTSM), Electronic Clinical Outcome Assessments (eCOA), Electronic Trial Master Files (eTMF), Site Connect, Study Training, among others. By utilizing these connected products, SCRI aims to streamline clinical trials from initiation to completion, automating essential processes and providing a unified experience at its research sites.

Jim Reilly, President of Veeva Development Cloud, remarked, “We are excited to work closely with SCRI to drive innovation in oncology research. In this unprecedented partnership, Veeva Clinical Platform will serve as the foundation for SCRI’s CRO and SMO clinical trials. By standardizing operations on a single platform, we can assist SCRI in conducting faster and more cost-effective trials.”

About Sarah Cannon Research Institute

The Sarah Cannon Research Institute is recognized globally as a leading oncology research organization dedicated to conducting localized clinical trials. For over 30 years, the SCRI has focused on advancing treatments for patients and has emerged as a pioneer in drug development. With a record of over 850 clinical trials and substantial contributions to research leading to the majority of FDA-approved cancer treatments in the past decade, SCRI’s network encompasses over 1,300 physicians who recruit patients for clinical studies across more than 200 sites in over 20 U.S. states.

About Veeva Systems

Veeva Systems is the global leader in cloud software for the life sciences industry. With a commitment to innovation, product excellence, and customer success, Veeva serves over 1,000 clients ranging from the largest global biopharmaceutical companies to emerging biotech firms. As a public company, Veeva is dedicated to balancing the interests of all stakeholders, including clients, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

In conclusion, the partnership between Veeva Systems and the Sarah Cannon Research Institute represents a pivotal moment in advancing oncology clinical trials. By leveraging technology to streamline processes, this collaboration holds the promise of accelerating the development of innovative treatments, ultimately improving outcomes for cancer patients worldwide.